RESUMO
Purpose To develop and validate a deep learning algorithm that predicts the final diagnosis of Alzheimer disease (AD), mild cognitive impairment, or neither at fluorine 18 (18F) fluorodeoxyglucose (FDG) PET of the brain and compare its performance to that of radiologic readers. Materials and Methods Prospective 18F-FDG PET brain images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2109 imaging studies from 2005 to 2017, 1002 patients) and retrospective independent test set (40 imaging studies from 2006 to 2016, 40 patients) were collected. Final clinical diagnosis at follow-up was recorded. Convolutional neural network of InceptionV3 architecture was trained on 90% of ADNI data set and tested on the remaining 10%, as well as the independent test set, with performance compared to radiologic readers. Model was analyzed with sensitivity, specificity, receiver operating characteristic (ROC), saliency map, and t-distributed stochastic neighbor embedding. Results The algorithm achieved area under the ROC curve of 0.98 (95% confidence interval: 0.94, 1.00) when evaluated on predicting the final clinical diagnosis of AD in the independent test set (82% specificity at 100% sensitivity), an average of 75.8 months prior to the final diagnosis, which in ROC space outperformed reader performance (57% [four of seven] sensitivity, 91% [30 of 33] specificity; P < .05). Saliency map demonstrated attention to known areas of interest but with focus on the entire brain. Conclusion By using fluorine 18 fluorodeoxyglucose PET of the brain, a deep learning algorithm developed for early prediction of Alzheimer disease achieved 82% specificity at 100% sensitivity, an average of 75.8 months prior to the final diagnosis. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Larvie in this issue.
Assuntos
Doença de Alzheimer/diagnóstico por imagem , Aprendizado Profundo , Interpretação de Imagem Assistida por Computador/métodos , Tomografia por Emissão de Pósitrons/métodos , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Disfunção Cognitiva/diagnóstico por imagem , Feminino , Fluordesoxiglucose F18/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
Gynecologic malignancies are the leading causes of cancer in women and they represent about 10 to 20% of all solid tumors. During the past few decades, technological advancements in the detection and staging have gained a pivotal role in all oncological processes, including the gynecological ones. Beyond ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging that are conventionally used for anatomical imaging, [18F]FDG imaging and its hybrid further development as PET/CT has become a crucial tool due of its ability to combine functional metabolic and anatomic information, and the ability to image the entire whole body in a single examination. Since the introduction of integrated hybrid PET/CT systems into clinical practice the accurate analysis of the images has detected a number of limitations and pitfalls. The purpose of this review was to describe in detail the different pitfalls related to the use of [18F]FDG PET/CT in the gynecological malignancies, providing imaging examples and discussing possible ways to avoid misinterpretations.
Assuntos
Fluordesoxiglucose F18 , Neoplasias dos Genitais Femininos/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Transporte Biológico , Feminino , Neoplasias dos Genitais Femininos/metabolismo , Neoplasias dos Genitais Femininos/patologia , Humanos , Processamento de Imagem Assistida por ComputadorAssuntos
Amiloidose/diagnóstico por imagem , Compostos de Anilina/farmacocinética , Cardiomiopatias/diagnóstico por imagem , Etilenoglicóis/farmacocinética , Transplante de Coração/efeitos adversos , Pulmão/diagnóstico por imagem , Complicações Pós-Operatórias/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , RecidivaRESUMO
BACKGROUND: Merkel cell carcinoma (MCC) is among the deadliest of cutaneous malignancies. A lack of consensus evaluation and treatment guidelines has hindered management of this disease. The utility of simultaneous positron emission tomography and computed tomography (PET/CT) has been demonstrated for a variety of tumors yet remains underinvestigated for MCC. OBJECTIVES: To report the value of fluorodeoxyglucose PET/CT imaging in the initial staging and ongoing management of individuals with MCC and to determine whether any patient or tumor characteristics may predict when PET/CT is more likely to have greater influence on medical decision-making. MATERIALS AND METHODS: A single-institution retrospective chart review was conducted of all patients diagnosed with MCC who underwent FDG-PET/CT scanning from 2007 to 2010. The outcome of each of these studies was evaluated as to the influence on patient staging and management. Patient clinical information and information on gross and microscopic tumor characteristics were collected and analyzed. RESULTS: Twenty patients underwent 39 PET/CT scans. Results of PET/CT imaging revealed previously unknown information related to MCC in four (20%) patients, leading to changes in management in three of these four cases. Three previously unknown neoplasms were detected. CONCLUSION: Fluorodeoxyglucose-positron emission tomography and computed tomography is a valuable tool for initial staging and to assess response to therapy of patients diagnosed with MCC. Larger prospective studies would be required to establish the optimal timing for this imaging modality.
Assuntos
Carcinoma de Célula de Merkel/diagnóstico por imagem , Carcinoma de Célula de Merkel/secundário , Imagem Multimodal , Tomografia por Emissão de Pósitrons , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/patologia , Tomografia Computadorizada por Raios X , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Célula de Merkel/terapia , Feminino , Fluordesoxiglucose F18 , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Compostos Radiofarmacêuticos , Estudos Retrospectivos , Neoplasias Cutâneas/terapiaRESUMO
BACKGROUND: No standardized field of view (FOV) currently exists for whole-body (WB) positron emission tomography/computed tomography (PET/CT). Limited WB PET/CT FOV can exclude portions of the head, upper, and lower extremities, because there is little perceived clinical benefit to be gained from imaging these areas. PURPOSE: To determine how often utilizing WB PET/CT changes the clinical stage and management compared to each of the limited WB FOVs used for PET/CT. MATERIAL AND METHODS: We retrospectively identified 556 oncologic patients (804 PET/CT studies) who underwent staging or restaging PET/CT between November 2010 and November 2011. Abnormal hypermetabolic areas that were suspicious for malignancy in areas that are outside of some of the limited fields of view including in the brain, scalp, and calvarium (above the orbital ridge), in the proximal upper extremity (distal to the humeral neck), distal upper extremity (beyond the elbow), proximal lower extremity (distal to the lesser trochanter), and distal lower extremity (beyond the knees) were recorded. RESULTS: A total of 8.5% (47/556) of patients had abnormal findings outside the most limited FOV (skull base to upper thighs) used in PET/CT. More patients had abnormal hypermetabolic lesions in the lower extremity (5.9%) than in the upper extremity (2.3%). Similarly, more patients had abnormal lesions in the proximal (6.5%) compared to the distal (1.4%) upper and lower extremities. The stage was only changed in one patient (0.2%), however new lesions noted in the brain changed management in six patients (1.1%). Melanoma, lymphoma, multiple myeloma, sarcomas and stage IV lung, breast, prostate, bladder, testicular, and renal cancer were more likely to have findings outside the most limited FOV (skull base to upper thighs). CONCLUSION: WB FOV detects additional sites of disease compared to the limited WB FOV, and although these lesions rarely change stage, some of these lesions may change clinical management.
Assuntos
Imagem Multimodal/métodos , Neoplasias/diagnóstico por imagem , Erros de Diagnóstico , Feminino , Fluordesoxiglucose F18 , Humanos , Masculino , Estadiamento de Neoplasias , Neoplasias/patologia , Tomografia por Emissão de Pósitrons , Interpretação de Imagem Radiográfica Assistida por Computador , Compostos Radiofarmacêuticos , Estudos Retrospectivos , Tomografia Computadorizada por Raios X , Imagem Corporal TotalRESUMO
Recent advances in positron emission tomography (PET) technology and reconstruction techniques have now made quantitative assessment using cardiac PET readily available in most cardiac PET imaging centers. Multiple PET myocardial perfusion imaging (MPI) radiopharmaceuticals are available for quantitative examination of myocardial ischemia, with each having distinct convenience and accuracy profile. Important properties of these radiopharmaceuticals ( 15 O-water, 13 N-ammonia, 82 Rb, 11 C-acetate, and 18 F-flurpiridaz) including radionuclide half-life, mean positron range in tissue, and the relationship between kinetic parameters and myocardial blood flow (MBF) are presented. Absolute quantification of MBF requires PET MPI to be performed with protocols that allow the generation of dynamic multiframes of reconstructed data. Using a tissue compartment model, the rate constant that governs the rate of PET MPI radiopharmaceutical extraction from the blood plasma to myocardial tissue is calculated. Then, this rate constant ( K1 ) is converted to MBF using an established extraction formula for each radiopharmaceutical. As most of the modern PET scanners acquire the data only in list mode, techniques of processing the list-mode data into dynamic multiframes are also reviewed. Finally, the impact of modern PET technologies such as PET/CT, PET/MR, total-body PET, machine learning/deep learning on comprehensive and quantitative assessment of myocardial ischemia is briefly described in this review.
Assuntos
Isquemia Miocárdica , Humanos , Isquemia Miocárdica/diagnóstico por imagem , Imagem de Perfusão do Miocárdio/métodos , Tomografia por Emissão de Pósitrons/métodos , Compostos RadiofarmacêuticosRESUMO
Prostate-specific membrane antigen (PSMA) PET has a higher accuracy than CT and bone scans to stage patients with prostate cancer. We do not understand how to apply clinical trial data based on conventional imaging to patients staged using PSMA PET. Therefore, we aimed to evaluate the ability of bone scans to detect osseous metastases using PSMA PET as a reference standard. Methods: In this multicenter retrospective diagnostic study, 167 patients with prostate cancer, who were imaged with bone scans and PSMA PET performed within 100 d, were included for analysis. Each study was interpreted by 3 masked readers, and the results of the PSMA PET were used as the reference standard. Endpoints were positive predictive value (PPV), negative predictive value (NPV), and specificity for bone scans. Additionally, interreader reproducibility, positivity rate, uptake on PSMA PET, and the number of lesions were evaluated. Results: In total, 167 patients were included, with 77 at initial staging, 60 in the biochemical recurrence and castration-sensitive prostate cancer setting, and 30 in the castration-resistant prostate cancer setting. In all patients, the PPV, NPV, and specificity for bone scans were 0.73 (95% CI, 0.61-0.82), 0.82 (95% CI, 0.74-0.88), and 0.82 (95% CI, 0.74-0.88), respectively. In patients at initial staging, the PPV, NPV, and specificity for bone scans were 0.43 (95% CI, 0.26-0.63), 0.94 (95% CI, 0.85-0.98), and 0.80 (95% CI, 0.68-0.88), respectively. Interreader agreement for bone disease was moderate for bone scans (Fleiss κ, 0.51) and substantial for the PSMA PET reference standard (Fleiss κ, 0.80). Conclusion: In this multicenter retrospective study, the PPV of bone scans was low in patients at initial staging, with 57% of positive bone scans being false positives. This suggests that a large proportion of patients considered low-volume metastatic by the bone scan actually had localized disease, which is critical when applying clinical data from trials such as the STAMPEDE M1 radiation therapy trial to patients being staged with PSMA PET.
Assuntos
Neoplasias Ósseas , Neoplasias da Próstata , Masculino , Humanos , Estudos Retrospectivos , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Reprodutibilidade dos Testes , Neoplasias da Próstata/patologia , Neoplasias Ósseas/diagnóstico por imagem , Neoplasias Ósseas/secundário , Radioisótopos de GálioRESUMO
We herein report a case of a false positive vasodilatory pharmacologic SPECT stress test in the setting of a left bundle branch block (LBBB). While this is more commonly seen with exercise stress testing, it can also occur with pharmacologic stress testing. In our SPECT exam, we illustrate the commonly mistaken septal/anteroseptal perfusion defects in those patients with a LBBB. PET stress testing may be more reliable for patients with LBBB.
Assuntos
Bloqueio de RamoRESUMO
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike 123I-MIBG, 124I-MIBG allows high-resolution PET. We evaluated 124I-MIBG PET/CT for its diagnostic performance as directly compared with paired 123I-MIBG scans. Methods: Before 131I-MIBG therapy, standard 123I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, including whole-body (anterior-posterior) planar imaging, focused-field-of-view SPECT/CT, and whole-body 124I-MIBG PET/CT (1.05 MBq/kg). After therapy, 2 of 7 patients also completed 124I-MIBG PET/CT as well as paired 123I-MIBG planar imaging and SPECT/CT. One patient underwent 124I-MIBG PET/CT only after therapy. We evaluated all 8 patients who showed at least 1 123I-MIBG-positive lesion with a total of 10 scans. In 8 pairs, 123I-MIBG and 124I-MIBG were performed within 1 mo of each other. The locations of identified lesions, the number of total lesions, and the curie scores were recorded for the 123I-MIBG and 124I-MIBG scans. Finally, for 5 patients who completed at least 3 PET/CT scans after administration of 124I-MIBG, we estimated the effective dose of 124I-MIBG. Results:123I-MIBG whole-body planar scans, focused-field-of-view SPECT/CT scans, and whole-body 124I-MIBG PET scans found 25, 32, and 87 total lesions, respectively. There was a statistically significant difference in lesion detection for 124I-MIBG PET/CT versus 123I-MIBG planar imaging (P < 0.0001) and 123I-MIBG SPECT/CT (P < 0.0001). The curie scores were also higher for 124I-MIBG PET/CT than for 123I-MIBG planar imaging and SPECT/CT in 6 of 10 patients. 124I-MIBG PET/CT demonstrated better detection of lesions throughout the body, including the chest, spine, head and neck, and extremities. The effective dose estimated for patient-specific 124I-MIBG was approximately 10 times that of 123I-MIBG; however, given that we administered a very low activity of 124I-MIBG (1.05 MBq/kg), the effective dose was only approximately twice that of 123I-MIBG despite the large difference in half-lives (100 vs. 13.2 h). Conclusion: The first-in-humans use of low-dose 124I-MIBG PET for monitoring disease burden demonstrated tumor detection capability superior to that of 123I-MIBG planar imaging and SPECT/CT.
Assuntos
3-Iodobenzilguanidina , Radioisótopos do Iodo , Neuroblastoma/diagnóstico por imagem , Neuroblastoma/patologia , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Pré-Escolar , Feminino , Humanos , Masculino , Metástase Neoplásica , Recidiva , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
BACKGROUND: Amino acid PET imaging of brain tumors has been shown to play an important role in predicting tumor grade, delineation of tumor margins, and differentiating tumor recurrence from the background of postradiation changes, but is not commonly used in clinical practice because of high cost. We propose that PET/MRI imaging of patients grouped to the day of tracer radiosynthesis will significantly decrease the cost of PET imaging, which will improve patient access to PET. METHODS: Seventeen patients with either primary brain tumors or metastatic brain tumors were recruited for imaging on 3T PET/MRI and were scanned on 4 separate days in groups of 3 to 5 patients. The first group of consecutively imaged patients contained 3 patients, followed by 2 groups of 5 patients, and a last group of 4 patients. RESULTS: For each of the patients, standard of care gadolinium-enhanced MRI and dynamic PET imaging with 18F-FDOPA amino acid tracer was obtained. The total cost savings of scanning 17 patients in batches of 4 as opposed to individual radiosynthesis was 48.5% ($28â 321). Semiquantitative analysis of tracer uptake in normal brain were performed with appropriate accumulation and expected subsequent washout. CONCLUSION: Amino acid PET tracers have been shown to play a critical role in the characterization of brain tumors but their adaptation to clinical practice has been limited because of the high cost of PET. Scheduling patient imaging to maximally use the radiosynthesis of imaging tracer significantly reduces the cost of PET and results in increased availability of PET tracer use in neuro-oncology.
RESUMO
PURPOSE: A pretherapy 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT) provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to 131I-MIBG treatment of neuroblastoma or pheochromocytoma. The aim of this work was to estimate human-equivalent internal radiation dose of 124I-MIBG using PET/CT data in a murine xenograft model. METHODS: Athymic mice subcutaneously implanted with NB1691 cells that express high levels of human norepinephrine transporter (n = 4) were imaged using small animal microPET/CT over 96 h (approximate imaging time points: 0.5, 2, 24, 52, and 96 h) after intravenous administration of 3.07-4.84 MBq of 124I-MIBG via tail vein. The tumors did not accumulate 124I-MIBG to a detectable level. All four animals were considered as control and organ radiation dosimetry was performed. Volumes of interest were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain pharmacokinetic data. Based on tabulated organ mass distributions for both mice and adult male human, preclinical pharmacokinetic data were extrapolated to their human-equivalent values. Radiation dose estimations for different age groups were performed using the OLINDA/EXM software with modified tissue weighting factors in the recent International Commission on Radiological Protection (ICRP) Publication 103. RESULTS: The mean effective dose from 124I-MIBG using weighting factors from ICRP 103 to the adult male was estimated at 0.25 mSv/MBq. In different age groups, effective doses using values from ICRP 103 were estimated as follows: Adult female: 0.34, 15-yr-old: 0.39 mSv/MBq, 10-yr-old: 0.58 mSv/MBq, 5-yr-old: 1.03 mSv/MBq, 1-yr-old: 1.92 mSv/MBq, and newborn: 3.75 mSv/ MBq. For comparison, the reported effective dose equivalent of 124I-NaI for adult male (25% thyroid uptake, MIRD Dose Estimate Report No. 5) was 6.5 mSv/MBq. CONCLUSIONS: The authors estimated human-equivalent internal radiation dose of 124I-MIBG using preclinical imaging data. As a reference, the effective dose estimation showed that 124I-MIBG would deliver less radiation dose than 124I-NaI, a radiotracer already being used in patients with thyroid cancer.
Assuntos
3-Iodobenzilguanidina , Tomografia por Emissão de Pósitrons/métodos , Doses de Radiação , 3-Iodobenzilguanidina/farmacocinética , Adolescente , Adulto , Animais , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Camundongos , Tomografia Computadorizada por Raios XRESUMO
With the routine availability of PET/CT imaging for oncologic purposes, there has been renewed interest in and acceptance of cardiac and neurologic applications of PET/CT. As our understanding of the pathophysiology underlying various pediatric heart diseases has improved, there has been a parallel advance in imaging modalities. Cardiac MR imaging and cardiac PET continue to improve in the pediatric domain. Molecular imaging holds promise to provide a more robust assessment of the cardiac pathophysiology in a 1-stop setting with less radiation exposure to the patient, an important consideration for the pediatric patient population.
Assuntos
Cardiopatias/diagnóstico por imagem , Pediatria/métodos , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Criança , Coração/diagnóstico por imagem , HumanosAssuntos
Cardiomiopatia Dilatada/diagnóstico por imagem , Fluordesoxiglucose F18 , Ventrículos do Coração/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Sarcoidose/diagnóstico por imagem , Disfunção Ventricular Direita/diagnóstico por imagem , Adulto , Diagnóstico Diferencial , Humanos , Masculino , Compostos RadiofarmacêuticosAssuntos
Injúria Renal Aguda , Fluordesoxiglucose F18 , Inibidores de Checkpoint Imunológico , Tomografia por Emissão de Pósitrons , Humanos , Injúria Renal Aguda/diagnóstico por imagem , Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/patologia , Inibidores de Checkpoint Imunológico/efeitos adversos , Masculino , Feminino , Pessoa de Meia-Idade , IdosoRESUMO
OBJECTIVES: Focal lesions in infants with congenital hyperinsulinism (HI) represent areas of adenomatosis that express a paternally derived ATP-sensitive potassium channel mutation due to embryonic loss of heterozygosity for the maternal 11p region. This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions. DESIGN: A total of 50 infants with HI unresponsive to medical therapy were studied. Patients were injected iv with [18F]DOPA, and PET scans were obtained for 50-60 min. Images were coregistered with abdominal computed tomography scans. PET scan interpretations were compared with histological diagnoses. RESULTS: The diagnosis of focal or diffuse HI was correct in 44 of the 50 cases (88%). [18F]DOPA PET identified focal areas of high uptake of radiopharmaceutical in 18 of 24 patients with focal disease. The locations of these lesions matched the areas of increased [18F]DOPA uptake on the PET scans in all of the cases. PET scan correctly located five lesions that could not be visualized at surgery. The positive predictive value of [18F]DOPA in diagnosing focal adenomatosis was 100%, and the negative predictive value was 81%. CONCLUSIONS: [18F]DOPA PET scans correctly diagnosed 75% of focal cases and were 100% accurate in identifying the location of the lesion. These results suggest that [18F]DOPA PET imaging provides a useful guide to surgical resection of focal adenomatosis and should be considered as a guide to surgery in all infants with congenital HI who have medically uncontrollable disease.
Assuntos
Di-Hidroxifenilalanina/análogos & derivados , Hiperinsulinismo/congênito , Hiperinsulinismo/diagnóstico por imagem , Compostos Radiofarmacêuticos , Biópsia , Humanos , Hiperinsulinismo/patologia , Interpretação de Imagem Assistida por Computador , Lactente , Recém-Nascido , Ilhotas Pancreáticas/patologia , Rim/patologia , Neoplasia Endócrina Múltipla/diagnóstico por imagem , Neoplasia Endócrina Múltipla/patologia , Pancreatectomia , Neoplasias Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/patologia , Tomografia por Emissão de Pósitrons , Tamanho da AmostraRESUMO
The head and neck is a complex anatomical region that can be evaluated using many imaging modalities. It is important to discern normal structures from ones that are affected by disease and to study how these structures change in their morphological and functional properties with aging. Therefore, using magnetic resonance imaging (MRI), we retrospectively evaluated volumes of the parotid glands, submandibular glands, thyroid gland, tongue, soft palate, and lingual tonsils in 64 subjects ages 13 to 81 years. Volume, attenuation (HU), and metabolic activity (maximum SUV) of the parotid, submandibular, and thyroid glands were assessed retrospectively using positron emission tomography/computed tomography (PET/CT) imaging in 35 subjects ages 10 to 76 years. Metabolic activity (maximum SUV) of the parotid, submandibular, and sublingual glands; tongue; adenoids; and tonsils (lingual and palatine) were evaluated retrospectively using PET imaging in 15 subjects ages 6 to 20 years. Metabolic volumetric products of the parotid, submandibular, and thyroid gland were calculated and analyzed with increasing age in subjects who underwent PET/CT imaging. Structures that exhibited statistically significant changes (P < 0.05) with increasing age included the submandibular glands, thyroid gland, soft palate, and adenoids. The CT volume of the submandibular glands increased with age, and the attenuation decreased with age with statistical significance. The thyroid gland volume, as measured using MRI, showed a statistically significant decrease with aging. The volume of the soft palate and lingual tonsils, as measured by MRI, exhibited a statistically significant decrease in volume with aging. The maximum SUV of the adenoids demonstrated a statistically significant decrease with aging. In conclusion, CT, MRI, and PET may be used to quantitatively and qualitatively assess structures of the head and neck and are useful in the assessment of structural and functional changes of these structures with aging.
Assuntos
Envelhecimento/patologia , Envelhecimento/fisiologia , Cabeça/anatomia & histologia , Cabeça/fisiologia , Pescoço/patologia , Pescoço/fisiologia , Vísceras/anatomia & histologia , Vísceras/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antropometria/métodos , Diagnóstico por Imagem/métodos , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada por Raios X/métodosRESUMO
It is useful to understand the normal changes in structure and function in the thorax that occur with age. Thus, we present the following quantitative preliminary data obtained from retrospective quantitative analysis of computed tomography (CT) and positron emission tomography (PET) examinations in subjects 0 to 90 years of age: Mean lung standard uptake values were found to significantly increase with increasing age and with increasing body mass index (BMI). Mean lung attenuation was seen to statistically significantly decrease with increasing age in subjects who had a CT scan, had a nonsignificant tendency to decrease with increasing age in subjects with a PET/CT scan, had a nonsignificant tendency to increase with increasing BMI, and was seen to significantly increase with increasing mean lung standard uptake values. Mean lung volumes were not noted to significantly change with increasing age in adult subjects whether or not they were normalized to the craniocaudal thoracic lengths, although mean lung volumes significantly increased with increasing age in pediatric subjects. Mean lung volumes had a nonsignificant tendency to decrease with increasing BMI, although normalized mean lung volumes significantly decreased with increasing BMI. Lung metabolic volumetric products were not noted to significantly change with increasing BMI or with increasing age. In this work, we also review the literature regarding normal structural and functional changes in the thorax with age.
Assuntos
Envelhecimento/patologia , Envelhecimento/fisiologia , Índice de Massa Corporal , Pulmão/anatomia & histologia , Pulmão/fisiologia , Tórax/anatomia & histologia , Tórax/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antropometria/métodos , Criança , Pré-Escolar , Diagnóstico por Imagem/métodos , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-IdadeRESUMO
Physicians have long told their patients that the doctor's job is to help patients "get as old as they can." As physicians, we have been aided in this objective by many other scientists in other disciplines. The entity of aging and its related changes blends imperceptibly with a variety of age-related diseases. However, these entities do appear to be separate though interrelated. Curing disease is important and a goal that we all work toward to add years to life expectancy. Here, we consider aging as it affects the heart and great vessels and as it serves to influence and support, if not cause, age-related cardiac diseases. This relationship is drawn as cardiac mechanics, hemodynamics, perfusion, metabolism and innervation, anatomy, and pathophysiology are each considered. The effects of aging are presented in 2 sections related to the early and recent "spikes" in aging related information. The latter is largely based in recent developments in chemistry, genetic engineering, molecular biology and the new imaging methods. The purpose of this manuscript is to present these new imaging methods, especially PET, and their impact on the second "spike." This is emphasized particularly in the second half of this review. As a method of demonstrating these imaging tools and their finest potential application, we decided to "showcase" atherosclerosis as the age-related disease for which these methods have made their greatest impact, for which yet more is promised, and for which the influence on longevity is most obvious. The application of positron emission tomography and other imaging methods to the characterization and image identification of atherosclerotic plaques and particularly the "vulnerable" plaque is emphasized. Yet, even with the eradication of coronary disease, the potential for very long life would not be likely. Only with the identification and eradication of the causative factors of aging can this possibility have a chance of becoming reality.
Assuntos
Envelhecimento/patologia , Envelhecimento/fisiologia , Aterosclerose/patologia , Aterosclerose/fisiopatologia , Sistema Cardiovascular/anatomia & histologia , Sistema Cardiovascular/fisiopatologia , Diagnóstico por Imagem/tendências , Humanos , Imageamento por Ressonância Magnética/tendências , Tomografia por Emissão de Pósitrons/tendências , Tomografia Computadorizada por Raios X/tendênciasRESUMO
With the size of the aged population in the United States expected to grow considerably during the next several decades, the number of imaging studies performed on such aged individuals will similarly increase. Thus, it is important to understand normal age-related changes in the structural and functional imaging appearance of the abdominal organs. We therefore present preliminary data and a review of the literature relevant to structural and functional changes in the abdominal organs of children and older adults. In a retrospective study of both adult and pediatric populations, we used computed tomography (CT), positron emission tomography (PET), and PET/CT imaging to investigate age-associated changes in size, attenuation, and metabolic function of the abdominal organs. Organs of interest include the liver, spleen, pancreas, kidneys, adrenal glands, stomach, small bowel, colon, and rectum. Although volumes of adult liver, spleen, pancreas, and kidneys do not change significantly with age, adult left and right adrenal gland volumes do significantly increase with age (r = 0.2823, P = 0.0334, and r = 0.3676, P = 0.0049, respectively). Also, the attenuation of adult liver (r = -0.2122, P = 0.0412), spleen (r = -0.4508, P < 0.0001), pancreas (r = -0.5124, P = 0.0007), and left and right adrenal gland (r = -0.5835, P < 0.0001 and r = -0.6135, P < 0.0001, respectively) decrease significantly with increasing age. Every organ studied in the pediatric population demonstrates a positive association between organ volume and age. Significant age-related changes in organ function are noted in the adult liver and small bowel, with the liver demonstrating a positive association between metabolic activity and age (r = 0.4434, P = 0.0029) and the small bowel showing an inverse association between mean small bowel standardize uptake value and age (r = -0.2435, P = 0.0174). Also, the maximum overall small bowel and colon metabolic activity in children increases with age (r = 0.6478, P = 0.0008). None of the other organs studied (ie, spleen, pancreas, adrenal glands, stomach, colon, rectum) demonstrate significant changes in metabolism with advancing age. The metabolic volumetric product (calculated as the product of organ volume and mean organ SUV) of the liver and spleen does not change significantly with age. In conclusion, various abdominal organs demonstrate differential changes in volume, attenuation, and/or metabolism with increasing age in pediatric and adult populations.
Assuntos
Abdome/anatomia & histologia , Abdome/fisiologia , Envelhecimento/patologia , Envelhecimento/fisiologia , Diagnóstico por Imagem/métodos , Vísceras/anatomia & histologia , Vísceras/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão/fisiologia , Pennsylvania , Tomografia por Emissão de Pósitrons/métodos , Estudos Retrospectivos , Tomografia Computadorizada por Raios X/métodosRESUMO
OBJECTIVES: To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism. STUDY DESIGN: Twenty-four infants with hyperinsulinism unresponsive to medical therapy were studied. Patients were injected intravenously with [18F]-DOPA, and PET scans were obtained for 1 hour. Images were coregistered with abdominal CT scans. RESULTS: The diagnosis of focal or diffuse hyperinsulinism was correct in 23 of the 24 cases (96%) and equivocal in 1 case. [18F]-DOPA PET identified focal areas of high uptake of radiopharmaceutical in 11 patients. Pathology results confirmed that all 11 had focal adenomatosis, and the locations of these lesions matched the areas of increased [18F]-DOPA uptake on the PET scans in all of the cases. CONCLUSIONS: [18F]-DOPA PET scans were 96% accurate in diagnosing focal or diffuse disease and 100% accurate in localizing the focal lesion. These results suggest that [18F]-DOPA PET imaging should be considered in all infants with congenital hyperinsulinism who need to have pancreatectomy.